#### **Baptist Health South Florida**

#### Scholarly Commons @ Baptist Health South Florida

All Publications

5-2020

# Transition from Fixed-dosing to Symptom-triggered Management of Alcohol Withdrawal Syndrome in the Intensive Care Unit of a Community Hospital

Marianela Robainas

South Miami Hospital, Marianela R@baptisthealth.net

Heidi Clarke

Baptist Hospital of Miami, heidic@baptisthealth.net

Claudia Chang
South Miami Hospital, claudiac@baptisthealth.net

Frances Ordieres Gonzalez
South Miami Hospital, FrancesO@baptisthealth.net

Lorenzo Porras Jr. South Miami Hospital, lorenzop@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Part of the Chemicals and Drugs Commons, Critical Care Commons, and the Pharmacy and Pharmaceutical Sciences Commons

#### Citation

Robainas, Marianela; Clarke, Heidi; Chang, Claudia; Ordieres Gonzalez, Frances; and Porras Jr., Lorenzo, "Transition from Fixed-dosing to Symptom-triggered Management of Alcohol Withdrawal Syndrome in the Intensive Care Unit of a Community Hospital" (2020). *All Publications*. 3537. https://scholarlycommons.baptisthealth.net/se-all-publications/3537

This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.

# Transition from Fixed-dosing to Symptom-triggered Management of Alcohol Withdrawal Syndrome in the Intensive Care Unit of a Community Hospital



Marianela Robainas, Pharm.D.

PGY-I Pharmacy Resident

South Miami Hospital

**Baptist Health South Florida** 

## Disclosure

- The authors of this presentation have no relevant financial or non-financial relationships in the products described and reviewed in this presentation
- Co-investigators
  - Heidi Clarke, PharmD, BCCCP
  - Claudia Chang, PharmD, BCPS
  - Frances Ordieres Gonzalez, PharmD
  - Lorenzo Porras, PharmD

## Abbreviations

- ADR: Adverse drug reaction
- AW: Alcohol withdrawal
- BZD: Benzodiazepine
- CIWA-Ar: Clinical Institute
   Withdrawal Assessment for Alcohol, revised
- GABA: Gamma-aminobutyric acid
- ICU: Intensive care unit

- IRB: Institutional review board
- IV: Intravenous
- LOS: Length of stay
- MINDS: Minnesota Detoxification Scale
- STT: Symptom-triggered therapy

# Objective

 Discuss the outcomes of a fixed-dose protocol for the management of AW in a community hospital

# Background

- In the United States, 2 to 7% of heavy alcohol users admitted to the hospital for general medical care will develop severe AW
- The most dangerous complications of AW are delirium tremens and seizures
- Benzodiazepines are considered first-line therapy
  - Alcohol is a central nervous system depressant which acts by modulation of GABA and glutamate activity
  - BZDs modulate binding of GABA to its receptor, increasing chloride ion influx and causing an inhibitory effect similar to alcohol

## Fixed-Dose versus STT

- Fixed-dose
  - Historically has been used to manage AW
  - BZDs are given at regular intervals
  - Additional doses are given as needed depending on severity of the symptoms according to AW scale scoring

#### STT

- BZDs are only administered when severity of symptoms necessitate, according to AW scale scoring
- Evidence shows that STT results in:
  - Lower doses of BZDs
  - Shorter BZD duration
  - Decreased rate of severe AW
  - Shorter duration of AW syndrome
  - Decreased complications

## Purpose


The purpose of this study was to evaluate the current BZD fixed-dose protocol and outline the transition to STT in the ICU

# Study Design

- Single center, IRB approved, retrospective chart review of patients treated for AW with a fixed-dose BZD protocol
- Study period: November 2017-December 2019

- Inclusion
  - Admitted to an ICU
  - Treatment for AW
  - Use of BZDs
- Exclusion
  - Age < 18 years</li>
  - Pregnancy
  - Allergy to BZD

# Screening



#### Outcomes

- Primary outcomes
  - Amount of BZD(s) used
    - Chlordiazepoxide daily mg dose
  - Duration of BZD therapy
    - Days of BZD use
  - Time to symptom control
    - Total days; beginning of symptoms to when symptoms were controlled

- Secondary outcomes
  - BZD-related adverse effects
    - Any BZD-related ADR such as somnolence, drowsiness, hypotension, or unresponsiveness
    - Reported by the nurse or physician
  - LOS in the ICU
    - Days spent in the ICU


# Statistical Methods

- Descriptive statistics
  - Mean
    - Duration of therapy
    - Time to symptom control
  - Median
    - Daily BZD use
    - LOS in the ICU



# Results: Primary Outcomes


- Daily BZD(s) used:
  - o 75 mg daily
- Duration of BZD therapy:
  - 5.4 days
- Time to symptom control:
  - 4.25 days





# Results: Secondary Outcomes

#### **BZD ADRs**



- BZD-related adverse effects
  - Approximately 42% of the patients who experienced an ADR received BZDs while asymptomatic or after symptoms were controlled
- LOS in the ICU
  - Median: 3 days
  - Majority of patients were transferred to the floors

# Additional Findings

- Only 21% of the prescribers used the AW PowerPlan
- Approximately 30% of patients had a CIWA-Ar score documented
  - For patients with a documented CIWA-Ar score, most had low scores for which treatment was not indicated
  - The use of CIWA-Ar did not necessarily correlate with the use of the PowerPlan
  - In patients with a CIWA-Ar score, reassessment of the score was not conducted

#### Conclusions

- The fixed-dose protocol led to patients receiving unnecessary treatment for AW
- Duration of BZD therapy was longer than time to symptom control, exposing patients to an extra day of unnecessary therapy
  - A large percentage of these patients experienced an ADR
- Areas for improvement for appropriate patient monitoring were identified, given the lack of use of the AW PowerPlan and poor documentation of CIWA-Ar scores

#### Limitations

- Retrospective chart review
- Small sample size
- Information assessed based on documentation
- Multiple sedative medications utilized
- Challenging to assess ADRs in intubated patients

#### Transition to STT

- Patients with AW will be treated using STT
- BZD of choice will be lorazepam oral or IV
- BZD will be administered based on a scale score (CIWA-Ar or MINDS)
- Score severity will determine BZD dose and monitoring parameters
  - Monitoring will be conducted by nurses
  - Parameters will be pre-determined to ensure proper escalation and deescalation of therapy
- Education will be provided to physicians, nurses, and pharmacists

## **Assessment Question**

- Which of the following outcomes is associated with fixed-dose benzodiazepine protocols?
  - A. Increased benzodiazepine use
  - B. Shorter duration of benzodiazepine use
  - C. Less sedation
  - D. Decreased length of stay

#### Assessment Answer

- Which of the following outcomes is associated with fixed-dose benzodiazepine protocols?
  - A. Increased benzodiazepine use
  - B. Shorter duration of benzodiazepine use
  - C. Less sedation
  - D. Decreased length of stay



## References

- Wood E, Albarqouni L, Tkachuk S, et al. Will this hospitalized patient develop severe alcohol withdrawal syndrome? The rational clinical examination systematic review. The Journal of the American Medical Association. 2018; 320(8), 825-833.
- Heavner J, Akgün M, Heavner S, et al. Implementation of an ICU-specific alcohol withdrawal syndrome management protocol reduces the meed for mechanical ventilation. The Journal of Human Pharmacology and Drug Therapy. 2018; 38(7), 701-713.
- Dixit D, Endicott J, Burry L, et al. Management of acute alcohol withdrawal syndrome in critically ill patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2016; 36(7), 797-822.